Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

ssessment of this modified scale over a two month treatment period of 150 mg elagolix, followed by twenty weeks of open-label treatment.

The blinded baseline data from the initial subjects screened for the Daisy Petal Study (0901) indicate that the modified daily non-menstrual pain scale reflects a wider dynamic range of pain scores which was lacking in the previous daily non-menstrual pelvic pain scale. This should allow for detection of treatment difference between elagolix and placebo for non-menstrual pain in the study population. The mean baseline score using the previous scale in the Lilac Petal Study (0702) was 0.83 (using the 0-3 scale on non-menstrual days), while preliminary Daisy Petal Study (0901) data with the new scale demonstrate a mean baseline score of approximately 1.5 (using the 0-3 scale on non-menstrual days), in the initial group of subjects recruited. Encouraged by the wider dynamic range of this modified scale, the Company has proposed a modest increase in the number of subjects for enrollment. This essentially moves the trial from a directional characterization of the endpoint (i.e., to estimate sample size for a Phase III trial) to a trial powered to provide statistical significance of the new non-menstrual pain endpoint versus placebo. The Company expects top-line data from the Daisy Petal Study (0901) in the second quarter of 2010.

"We are pleased with the outcome of the Type C meeting with the FDA," said Chris O'Brien, Chief Medical Officer. "Given the dynamic range of the daily non-menstrual pain endpoint in our baseline assessments, we were able to quickly estimate the appropriate sample size needed to assess this endpoint for statistical significance, and made the decision to increase our patient population accordingly."

The Tulip Petal Study (0703) has completed subject randomization (n=174) and treatment through Week 12 in Central Eastern Europe. This study is designed as a randomized, double-blind,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... PRINCETON, N.J. , Aug. 28, 2015  IP Shakti, ... Prediqtus, LLC. ... "Our new corporate identity signifies our ... the world,s first predictive analytics platform for patent claim validity." ... with the launch of the proprietary AIA Shield™ platform, the ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
(Date:8/30/2015)... ... 2015 , ... The law firm of Tomasik Kotin ... recently elected to membership in the American Board of Trial Advocates (ABOTA). ... outstanding professionalism. , ABOTA is an invitation-only, national organization comprised of judges ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ProDrop Particles includes ... Each preset contains 15 seconds of unique footage that users can shrink and stretch ... zoom, attract and more. Users can customize color, brightness, scale, speed, range, and flare ...
Breaking Medicine News(10 mins):Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... THURSDAY, Feb. 23 (HealthDay News) -- Children with ... attention-deficit hyperactivity disorder (ADHD) and other related disorders, but ... Researchers analyzed data from more than 1,000 U.S. teens ... of psychiatric medications in those with autism, ADHD and ...
... Reinberg HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay ... but this winter,s flu season is finally here, say experts ... They report that flu activity picked up in the past ... influenza season since 1987-1988. Lab-confirmed cases of influenza have now ...
... CINCINNATI Scientists have developed a unique compound ... blood cells known to fuel ailments like cancer ... Past attempts to identify new compounds ... molecules in cells have been complicated by toxicity ...
... WEDNESDAY, Feb. 22 (HealthDay News) -- Melanoma that has spread ... but a new drug appears to double survival for those ... A mutation in the BRAF protein occurs in about ... a drug approved by the U.S. Food and Drug Administration ...
... Feb. 23 (HealthDay News) -- The first molecular evidence linking ... death could lead to new methods of diagnosis and therapy ... study suggests. Abnormal heart rhythms called ventricular arrhythmias are ... the primary cause of death from heart disease. Experts have ...
... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... might just be the beginning of your spring allergies ... had warmer-than-average winter weather, which is causing trees to ... Stanley Fineman, president of the American College of Allergy, ...
Cached Medicine News:Health News:Meds for Autism Not Well Understood: Study 2Health News:Flu Season Off to a Very Late Start: CDC 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 3Health News:New Melanoma Drug May Extend Survival 2Health News:New Melanoma Drug May Extend Survival 3Health News:Study Links 'Body Clock' to Sudden Cardiac Death 2Health News:Mild Winter Heralds Early Sneezin' Season 2Health News:Mild Winter Heralds Early Sneezin' Season 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: